High risk of gastrointestinal hemorrhage in patients with systemic sclerosis

Lin, Yi-Ting; Chuang, Yun-Shiuan; Wang, Jiunn-Wei; Wu, Ping-Hsun

doi:10.1186/s13075-019-2078-5

Cited by 8 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it was observed that SSc can be an independent risk factor for GI bleeding events with an HR of 2.98 (95%CI: 2.21-4.02)[ 84 ]. GAVE is part of the spectrum of vascular disease in these patients[ 16 , 24 ].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Gastrointestinal manifestations of systemic sclerosis: An updated review

Lúquez-Mindiola

Atuesta

Aldana

2021

WJCC

View full text Add to dashboard Cite

Systemic sclerosis is an autoimmune disease characterized by vascular disease, fibrosis of the skin, and internal organ dysfunction. Gastrointestinal involvement is the most frequent complication of internal organs, impacting up to 90% of patients. Gastrointestinal involvement can affect any region of the gastrointestinal tract from the mouth to the anus, with a predominance of disorders being observed at the level of the upper digestive tract. The gastrointestinal involvement primarily involves the esophagus, small bowel, and rectum. The severity of gastrointestinal involvement affects quality of life and is a marker of worse prognosis and mortality in these patients. In this review, we describe the current findings regarding gastrointestinal involvement by this entity.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 99%

Gastrointestinal manifestations of systemic sclerosis: An updated review

Lúquez-Mindiola

Atuesta

Aldana

2021

WJCC

View full text Add to dashboard Cite

show abstract

“…The systemic scleroderma further increases the risk for fatal manifestations, including Ogilvie syndrome or intestinal pseudo-obstruction [11]. GI symptoms of 5.3-55.6% of systemic scleroderma patients reportedly increase their risk of malnutrition [12].…”

Section: Gastrointestinal Manifestations In Sclerodermamentioning

confidence: 99%

“…Lifestyle modification is also recommended (avoidance of large and late-night meals) [1,3] . Gastric involvement 50% [10] -Gastroparesis 50% [10] -Gastric Antral Vascular Ectasia (GAVE) 5.6-22.3% [3,10] Gastric Bleeding Ectasis 0.6-0.8% [11] -Upper GI Bleeding 3.2% [12] 1. Gastric emptying study [1,3,9] .…”

Section: Good Oral Hygiene and Artificialmentioning

confidence: 99%

See 1 more Smart Citation

Gastrointestinal Involvement in Systemic Sclerosis

Nassar¹,

Ghernautan²,

Nso³

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction: The gastrointestinal tract (GI) is the second most affected organ system in systemic sclerosis or systemic/localized scleroderma (SSc) and is an important topic for research. Approximately 90% of patients with scleroderma exhibit pathology of the GI tract. The systemic scleroderma has the potential to impact any part of the gastrointestinal tract, between the oral cavity and anorectum. The pathological complications of scleroderma adversely impact the health-related quality of life of the affected patients and increase the treatment burden of patients and medical professionals. Study Aim: We summarized the epidemiology, commonly reported clinical manifestations, complications, and available therapies for treating the GI pathology in systemic scleroderma patients. Methodology: We performed a literature review using the keywords "systemic sclerosis," "scleroderma," "GI manifestations in scleroderma," and "GI complications of scleroderma" across databases, including Google Scholar, Medline, Embase, and PubMed. We also analyzed a range of case reports concerning scleroderma manifestations and treatment modalities. Results: Our research revealed the annual incidence of SSc attributing to19.3 cases per million adults in the United States. We found the highest incidence of systemic scleroderma in patients within the age range of 44-55 years. Our results affirmed 5:1 incidence of systemic scleroderma that confirmed the higher impact of this disease condition in females than male populations. We found that the gastrointestinal manifestations of systemic scleroderma predominantly elevate the morbidity and mortality incidence among the affected patients. Esophageal and intestinal manifestations impact 90% and 40-70% of patients with systemic scleroderma. The small bowel hypomotility and small intestinal bacterial overgrowth (SIBO) in systemic scleroderma cases trigger the episodes of malabsorption and malnutrition that eventually add to 50% of the mortality rate. Systemic sclerosis is associated with the high incidence of fecal incontinence that triggers depression and its deleterious mental health manifestations in many clinical scenarios. Conclusion: The gastrointestinal complications in systemic sclerosis potentially deteriorate the daily living activities of the affected patients. The systematic management of the gastrointestinal complications of systemic scleroderma warrants multidisciplinary approaches. Prospective studies should focus on developing targeted therapies for improving the recovery patterns and prognostic outcomes in systemic scleroderma cases.

show abstract

“…[ 2 ] The EULAR Scleroderma Trial and Research cohort revealed 6.6% of deaths from SSc that resulted from GI complications among elderly patients and patients with diffuse skin involvement. [ 7 , 9 , 10 ] The affected patients developed a high frequency of GI symptoms at an early stage of systemic scleroderma.…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal involvement in systemic sclerosis: An updated review

et al. 2022

View full text Add to dashboard Cite

The gastrointestinal tract (GI) is the second most affected organ system in individuals suffering from systemic/localized scleroderma (SSc) or localized scleroderma. SSc can affect any part of the GI, between the oral cavity and anorectum. The annual incidence of SSc in the United States is estimated to be 19.3 cases per million adults, with the highest incidence reported in people aged 44 to 55. Females are 5 times more likely than males to suffer from SSc. Morbidity and mortality rates associated with SSc are predominantly elevated among patients with GI manifestations. Esophageal and intestinal manifestations impact 90% and 40% to 70% of patients with systemic scleroderma, respectively. SSc patients are known to suffer from small bowel hypomotility and small intestinal bacterial overgrowth, which cause malabsorption and malnutrition, ultimately contributing to the 50% mortality rate. Fecal incontinence is a common symptom of SSc that can lead to depression. SSc patients may suffer from gastrointestinal complications that can negatively impact their quality of life on a daily basis. Multidisciplinary approaches are necessary for systematically managing gastrointestinal complications associated with SSc. A prospective study should focus on developing targeted therapies to improve recovery patterns and prognosis in cases of SSc. This article summarizes the epidemiology, commonly reported clinical manifestations, complications, and available treatments for treating GI pathology in SSc patients.

show abstract

High risk of gastrointestinal hemorrhage in patients with systemic sclerosis

Cited by 8 publications

References 33 publications

Gastrointestinal manifestations of systemic sclerosis: An updated review

Gastrointestinal manifestations of systemic sclerosis: An updated review

Gastrointestinal Involvement in Systemic Sclerosis

Gastrointestinal involvement in systemic sclerosis: An updated review

Contact Info

Product

Resources

About